AQR Capital Management LLC Grows Position in Alphatec Holdings, Inc. (NASDAQ:ATEC)

AQR Capital Management LLC grew its holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 18.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 628,958 shares of the medical technology company's stock after acquiring an additional 98,622 shares during the quarter. AQR Capital Management LLC owned 0.44% of Alphatec worth $5,774,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of ATEC. Barclays PLC grew its position in Alphatec by 362.3% in the third quarter. Barclays PLC now owns 170,546 shares of the medical technology company's stock valued at $948,000 after purchasing an additional 133,653 shares in the last quarter. Courier Capital LLC grew its holdings in shares of Alphatec by 76.9% in the 4th quarter. Courier Capital LLC now owns 69,000 shares of the medical technology company's stock valued at $633,000 after acquiring an additional 30,000 shares in the last quarter. Ballentine Partners LLC acquired a new stake in shares of Alphatec in the fourth quarter valued at about $120,000. Nisa Investment Advisors LLC raised its holdings in Alphatec by 973.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company's stock worth $43,000 after acquiring an additional 4,234 shares in the last quarter. Finally, Mount Yale Investment Advisors LLC acquired a new position in Alphatec during the fourth quarter valued at approximately $152,000. Institutional investors and hedge funds own 66.35% of the company's stock.

Insiders Place Their Bets

In other Alphatec news, CEO Patrick Miles sold 32,393 shares of the stock in a transaction on Wednesday, February 26th. The stock was sold at an average price of $10.89, for a total transaction of $352,759.77. Following the sale, the chief executive officer now directly owns 5,940,391 shares in the company, valued at approximately $64,690,857.99. This trade represents a 0.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP David Sponsel sold 33,732 shares of the firm's stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $10.83, for a total transaction of $365,317.56. Following the sale, the executive vice president now directly owns 668,977 shares in the company, valued at approximately $7,245,020.91. The trade was a 4.80 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 126,945 shares of company stock worth $1,416,352. 20.90% of the stock is currently owned by company insiders.

Alphatec Price Performance

Shares of ATEC traded down $0.52 during midday trading on Friday, hitting $12.22. 1,888,232 shares of the company traded hands, compared to its average volume of 2,046,862. The stock has a 50-day moving average of $10.50 and a 200-day moving average of $10.16. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. Alphatec Holdings, Inc. has a one year low of $4.88 and a one year high of $12.82. The firm has a market cap of $1.79 billion, a P/E ratio of -9.55 and a beta of 1.06.

Alphatec (NASDAQ:ATEC - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.23). The company had revenue of $169.18 million during the quarter, compared to analysts' expectations of $167.57 million. Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The firm's revenue was up 22.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.34) earnings per share. As a group, sell-side analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ATEC has been the subject of several recent analyst reports. Needham & Company LLC reiterated a "buy" rating and issued a $16.00 target price on shares of Alphatec in a research note on Friday, May 2nd. HC Wainwright reissued a "buy" rating and issued a $20.00 price target on shares of Alphatec in a report on Monday, April 14th. StockNews.com raised Alphatec from a "sell" rating to a "hold" rating in a research report on Friday, February 28th. Piper Sandler reissued an "overweight" rating and set a $15.00 price target (up from $13.00) on shares of Alphatec in a report on Friday, May 2nd. Finally, Barclays increased their price objective on Alphatec from $20.00 to $21.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 22nd. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat, Alphatec has a consensus rating of "Moderate Buy" and an average price target of $17.89.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.